LGVN: Longeveron Inc Price-to-Revenue Multiple

Symbol and logo of brand Longeveron Corp (LGVN)

Longeveron Inc. develops cell therapies to combat age-related pathologies, protecting its innovations with L-CELL patents. The price-to-sales ratio on the GURU.Markets terminal illustrates the asset's dynamics, where the 6.60 value captures the metric level. Growth is supported by the success of Lomecel-B trials and grants. The strategy is based on niche research, avoiding price competition by competing for capital.

LGVN longeveron.com Market Cap to Revenue (07/04/2022 - 11/14/2026)

Metric breakdowns and analytics for Longeveron Corp (LGVN)

- stock price and consensus target price:
Share Price longeveron.com|LGVN - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Longeveron Corp|LGVN - Enterprise Value
- book capitalization data:
Net Asset Value per Share Longeveron|LGVN - Company Net Assets|Market Value to Book Value Ratio longeveron.com|LGVN - Company Total Assets
- debt obligations and liquidity statistics:
Debt to Capital Longeveron Inc.|LGVN - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Longeveron Corporation|LGVN - Company Debts|Debts to Book Value Longeveron Corp|LGVN - Company Long-Term Debt|Company Short-Term Indebtedness Longeveron|Intermediate Coverage Ratio longeveron.com
- earnings and multiples data:
LGVN - Net Profit|Company Profit Forecast Longeveron Inc.|LGVN - Price to Earnings Ratio|Price to Future Earnings Ratio Longeveron Inc|LGVN - PEG Multiple|Enterprise Value to EBITDA Ratio Longeveron Corp|LGVN - Operating profit before deduction of amortization|Net earnings per share for the last four quarters Longeveron|LGVN - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months longeveron.com|LGVN - Earnings growth in current year|Net earnings per one share growth forecast for next year Longeveron Inc.
- sales revenue and business income indicators:
LGVN - Company Sales|Company Projected Revenue longeveron.com|LGVN - Price-to-Revenue Ratio|Market Cap to Projected Revenue Longeveron Corp
Fundamental company analysis:LGVN - longeveron.com
Mass-produced product of Longeveron Corporation

The P/S ratio determines the market value of a business relative to its annual revenue, allowing for an assessment of the premium investors pay per unit of revenue. For Longeveron Inc. (LGVN), this metric reflects the capitalization of costs associated with strict compliance with ESG standards and bioethics during the development of cell therapy. By analyzing the price-to-sales chart, one can identify the gap between market expectations and actual sales. A balanced ratio confirms the fundamental stability and quality of the company's assets.

Competitors of Longeveron Inc.

mesoblast.com - Market Cap to Revenue Ratio|P/S Multiple LCTX (Lineage Cell Therapeutics, Inc.)|Price-to-Revenue Multiple Surrozen Inc|Cryo-Cell International Inc - P/S Multiple|Price to Sales FibroBiologics, Inc.|BRTX (biorestorative.com) - Market Cap to Revenue|CELZ (Creative Medical Technology Holdings) - Price-to-Revenue Ratio